Page last updated: 2024-09-04

torcetrapib and Atherosclerosis

torcetrapib has been researched along with Atherosclerosis in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (69.57)	29.6817
2010's	14 (30.43)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alaupovic, P; Bagdade, J; Barter, P; Quiroga, C	1
Abdallah, M; Abi Rafeh, N; Bhat, T; El-Sayegh, S; Kalantar-Zadeh, K; Khoueiry, G; Lafferty, J; Raza, M; Saiful, F	1
deGoma, EM; Rader, DJ	1
Adam, LP; Bilder, D; Chang, M; Chen, AY; Chen, XQ; Finlay, HJ; Gordon, DA; Harikrishnan, LS; Huang, CS; Kamau, MG; Lawrence, RM; Leith, L; Levesque, P; Li, D; Li, J; Li, JP; Li, YX; Miller, MM; Poss, MA; Qiao, JX; Rampulla, R; Salvati, ME; Shen, H; Sleph, PG; Smith, D; Taylor, DS; Wang, TC; Wexler, RR; Wu, DR; Xu, C; Yang, RZ; Yin, X; Zhuang, S	1
Quintão, EC	1
Kastelein, JJ; Stroes, ES; van Leuven, SI	1
Ahmed, MH	1
Neeli, H; Rader, DJ	1
Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL	1
Pfeffer, MA; Sacks, FM	1
Olsson, AG	2
Feuerstein, G; Jin, W; Packard, C; Rader, D; Zhao, L	1
Shinkai, H	1
Stroes, ES; Vergeer, M	1
Böhm, M; Laufs, U; Pöss, J	1
Rizzoni, D; Rossi, GP	1
Barter, PJ	1
Mombelli, G; Sirtori, CR	1
Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD	1
Toth, PP	1
Schaefer, JR	1
Deanfield, J; Kastelein, J; Landmesser, U; Lüscher, TF; von Eckardstein, A	1
Kaski, JC	1
Burnett, JR	1
Barter, PJ; Kastelein, JJ	1
Clark, RW	1
El-Harchaoui, K; Kastelein, JJ; Kuivenhoven, JA; Van der Steeg, WA	1
Chapman, MJ	1
Davidson, MH; McKenney, JM; Revkin, JH; Shear, CL	1
Ansell, B; Hobbs, FD	1
Bourassa, PA; Gao, F; Milici, AJ; Morehouse, LA; Rothblat, GH; Sand, TM; Sugarman, ED; Zimetti, F	1
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI	1
Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI	1
Guo, CB; Li, S	1
Opar, A	1
Mazzone, T	1
Suckling, K	2
Orloff, DG	1
Dueñas-Laita, A; Pérez-Castrillon, JL	1
Hegele, RA; Joy, T	1
Heinecke, JW; Oram, JF	1
Conca, P; Franceschini, G	1
de Haan, W; de Vries-van der Weij, J; Gautier, T; Havekes, LM; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; van der Hoorn, JW; Westerterp, M	1
Duriez, P	1

Reviews

22 review(s) available for torcetrapib and Atherosclerosis

Article	Year
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy. International urology and nephrology, 2014, Volume: 46, Issue:1 Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Niacin; PPAR alpha; Quinolines; Renal Insufficiency, Chronic; Sulfonamides; Sulfonic Acids; Uremia	2014
Future of cholesteryl ester transfer protein inhibitors. Annual review of medicine, 2014, Volume: 65 Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Benzodiazepines; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds	2014
The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel? European journal of clinical investigation, 2016, Volume: 46, Issue:6 Topics: Amides; Animals; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Benzodiazepines; Cholesterol Ester Transfer Proteins; Esters; Humans; Hypercholesterolemia; Mice; Oxazolidinones; Quinolines; Rabbits; Sulfhydryl Compounds	2016
High-density lipoprotein: a fall from grace? Annals of medicine, 2008, Volume: 40, Issue:8 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Humans; Quinolines	2008
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines	2008
Leapfrogging data: no shortcuts for safety or efficacy information. Circulation, 2008, Dec-09, Volume: 118, Issue:24 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Drug-Related Side Effects and Adverse Reactions; Humans; Quinolines	2008
Is high HDL cholesterol always good? Annals of medicine, 2009, Volume: 41, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Humans; Quinolines; Risk; Treatment Outcome	2009
Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Expert opinion on therapeutic patents, 2009, Volume: 19, Issue:9 Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Esters; Humans; Oxazolidinones; Patents as Topic; Quinolines; Sulfhydryl Compounds	2009
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. The American journal of cardiology, 2009, Nov-16, Volume: 104, Issue:10 Suppl Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds	2009
[HDL and CETP in atherogenesis]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:5 Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome	2010
CETP Inhibition: does the future look promising? Current cardiology reports, 2011, Volume: 13, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Incidence; Male; Quinolines; Risk Factors	2011
[HDL level or HDL function as the primary target in preventive cardiology]. Herz, 2012, Volume: 37, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation	2012
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. Journal of the American College of Cardiology, 2006, Feb-07, Volume: 47, Issue:3 Topics: Amides; Animals; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Esters; Glycoproteins; Humans; Quinolines; Risk Factors; Sulfhydryl Compounds; Vaccines	2006
Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Current opinion in pharmacology, 2006, Volume: 6, Issue:2 Topics: Amides; Atherosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Female; Glycoproteins; Humans; Lipoproteins, HDL; Male; Quinolines; Sulfhydryl Compounds	2006
Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease? Current drug targets. Cardiovascular & haematological disorders, 2005, Volume: 5, Issue:6 Topics: Amides; Atherosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Esters; Glycoproteins; Humans; Models, Biological; Quinolines; Sulfhydryl Compounds	2005
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology & therapeutics, 2006, Volume: 111, Issue:3 Topics: Amides; Animals; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol, HDL; Coronary Disease; Esters; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; PPAR alpha; PPAR delta; PPAR gamma; Quinolines; Sulfhydryl Compounds	2006
The potential for CETP inhibition to reduce cardiovascular disease risk. Current medical research and opinion, 2006, Volume: 22, Issue:12 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Quinolines; Risk Factors; Vaccination	2006
[Advances in the study of anti-atherosclerosis drugs]. Yao xue xue bao = Acta pharmaceutica Sinica, 2007, Volume: 42, Issue:3 Topics: Apolipoprotein A-I; Atherosclerosis; Benzoates; Benzylamines; Cholesterol Ester Transfer Proteins; DNA-Binding Proteins; Humans; Liver X Receptors; Molecular Structure; Orphan Nuclear Receptors; Oxazines; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Quinolines; Receptors, Cytoplasmic and Nuclear	2007
Regulatory considerations in the development of high-density lipoprotein therapies. The American journal of cardiology, 2007, Dec-03, Volume: 100, Issue:11 A Topics: Anticholesteremic Agents; Atherosclerosis; Biomarkers; Drug Approval; Humans; Lipoproteins, HDL; Quinolines	2007
New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib. Recent patents on cardiovascular drug discovery, 2006, Volume: 1, Issue:1 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Macrophages; Quinolines	2006
Is raising HDL a futile strategy for atheroprotection? Nature reviews. Drug discovery, 2008, Volume: 7, Issue:2 Topics: Amides; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Atherosclerosis; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Esters; Humans; Lipoproteins, HDL; Phospholipids; Quinolines; Sulfhydryl Compounds; Treatment Outcome	2008
Synthetic HDL as a new treatment for atherosclerosis regression: has the time come? Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:4 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Humans; Quinolines	2008

Trials

5 trial(s) available for torcetrapib and Atherosclerosis

Article	Year
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation, 2008, Dec-09, Volume: 118, Issue:24 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol Ester Transfer Proteins; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mineralocorticoids; Pyrroles; Quinolines	2008
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2011
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. Journal of the American College of Cardiology, 2006, Nov-07, Volume: 48, Issue:9 Topics: Adult; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Double-Blind Method; Female; Humans; Male; Middle Aged; Quinolines	2006
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2007
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography	2007

Other Studies

19 other study(ies) available for torcetrapib and Atherosclerosis

Article	Year
Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). The American journal of cardiology, 2017, 06-01, Volume: 119, Issue:11 Topics: Anticholesteremic Agents; Apolipoprotein C-III; Apoproteins; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Quinolines; Retrospective Studies; Treatment Outcome	2017
Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311). Journal of medicinal chemistry, 2015, Nov-25, Volume: 58, Issue:22 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Benzamides; Benzylamines; Blood Pressure; Cell Line; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cytochrome P-450 CYP11B2; Dogs; Drug Discovery; Humans; Macaca fascicularis; Male; Mesocricetus; Mice; Mice, Transgenic; Motor Activity; Quinolines; Rats; Rats, Sprague-Dawley	2015
Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream? Diabetes technology & therapeutics, 2008, Volume: 10, Issue:4 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Humans; Quinolines	2008
A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atheroscle Biochemical pharmacology, 2009, Aug-15, Volume: 78, Issue:4 Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Drug Discovery; Forecasting; Humans; Lipid Metabolism; Quinolines; Risk Factors; Treatment Failure	2009
Therapy: raising HDL cholesterol levels: a flight of Icarus? Nature reviews. Endocrinology, 2010, Volume: 6, Issue:5 Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Niacin; Quinolines	2010
The relationship between cholesteryl ester transfer protein and cardiovascular risk. Clinical chemistry, 2010, Volume: 56, Issue:10 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Genetic Predisposition to Disease; Humans; Polymorphism, Genetic; Quinolines; Risk	2010
Cholesteryl ester transfer protein antagonism by drugs--a poor choice. Clinical chemistry, 2010, Volume: 56, Issue:10 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk	2010
Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. European heart journal, 2012, Volume: 33, Issue:14 Topics: Acute Coronary Syndrome; Amides; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Early Termination of Clinical Trials; Esters; Humans; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds	2012
HDL- cholesterol: a nut too hard to crack? Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Niacin; Quinolines	2012
Torcetrapib + atorvastatin (Pfizer). Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:9 Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines	2005
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. Journal of lipid research, 2007, Volume: 48, Issue:6 Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Biological Transport; Cell Line, Tumor; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Atherogenic; Disease Susceptibility; Male; Quinolines; Rabbits; Regression Analysis	2007
Where now for new drugs for atherosclerosis? Nature reviews. Drug discovery, 2007, Volume: 6, Issue:5 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Humans; Quinolines	2007
HDL cholesterol and atherosclerosis. Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Pyrroles; Quinolines; Tunica Intima	2007
The continuing complexities of high-density lipoprotein metabolism in drug discovery and development. Expert opinion on therapeutic targets, 2007, Volume: 11, Issue:9 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Drug Design; Humans; Lipoproteins, HDL; Niacin; Quinolines	2007
When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Liver; Quinolines	2007
Will CETP inhibition survive the demise of torcetrapib? Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Humans; Quinolines; Risk Assessment; Risk Factors; Treatment Failure	2008
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:7 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines	2008
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation, 2008, May-13, Volume: 117, Issue:19 Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Synergism; Heptanoic Acids; Inflammation; Mice; Mice, Inbred Strains; Pyrroles; Quinolines	2008
Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein? Current atherosclerosis reports, 2008, Volume: 10, Issue:3 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Heart Diseases; Humans; Oxazolidinones; Quinolines; Risk Factors	2008